{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:52:00Z","timestamp":1785369120009,"version":"3.55.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","award":["0691"],"award-info":[{"award-number":["0691"]}],"id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["496563"],"award-info":[{"award-number":["496563"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical guidance in Canada and the United States recommends faster methadone dose titration for individuals using fentanyl. An initial dose increase is recommended between days 4 and 6, but the impact on patient outcomes remains unclear, particularly when provided in an outpatient setting. Therefore, we evaluated the association between early methadone dose titration (i.e., within treatment days 4\u20136) and treatment discontinuation and opioid toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective propensity-score weighted cohort study of Ontario residents who initiated methadone in an outpatient setting between January 2017 and December 2022. Exposure was defined as provision of a dose titration between treatment days 4\u20136, with the index date defined as the first date of dose increase. For unexposed individuals, the index date was randomly assigned and followed the same distribution as those exposed. Individuals were followed for up to 181 days following index date for study outcomes. Primary outcomes included methadone discontinuation and opioid toxicity, using an intention-to-treat approach. Secondary outcomes included methadone versus non-methadone-related toxicity while on treatment. We fit a propensity-score model to estimate the probability of dose titration, conditional on baseline demographic and clinical (e.g., comorbidities, past medication use) variables. Propensity score weighted Cox proportional hazard models were then estimated to determine the association between early dose titration and study outcomes. Among 13,560 incident methadone recipients (61.4% [\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20098,322] provided early dose titration), the mean age was 36.5 years old, and approximately one-third were female. Individuals who received an early dose titration had a lower weighted hazard of discontinuation, which was most pronounced during the first seven days of follow-up (weighted hazard ratio [wHR]: 0.55; 95% confidence interval [CI]: 0.51, 0.60), with attenuation towards the null over time. The observed weighted rate of opioid toxicity was lower among those exposed versus unexposed (10.1 versus 12.3 per 100 person-years; wHR: 0.82; [95% CI: 0.69, 0.97]). Early dose titration was not associated with opioid toxicity while on treatment. Most toxicities were attributed to non-methadone opioids (exposed: 3.89 per 100 person-years versus unexposed: 4.06 per 100 person-years; wHR: 1.00; [95% CI: 0.70, 1.44]). Methadone-related toxicity while on treatment remained low and comparable between exposed and unexposed groups (2.02 versus 2.65 per 100 person-years; wHR: 0.80; [95% CI: 0.46, 1.41]). The main study limitation is the lack of information on drug use history and time-varying clinical factors that may influence both dose titration and subsequent outcomes, introducing the potential for residual confounding.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This population-based analysis demonstrated that early methadone dose titration was associated with improved treatment retention and lower hazard of opioid toxicity. Logistical barriers that hinder timely provision of dose increases must be addressed to improve methadone retention among people who use fentanyl.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004748","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:22:37Z","timestamp":1775755357000},"page":"e1004748","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between early methadone dose titration and treatment discontinuation and opioid toxicity: A retrospective cohort study"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2572-0170","authenticated-orcid":true,"given":"Ria","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-7407","authenticated-orcid":true,"given":"Nikki","family":"Bozinoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Sproule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8374-6518","authenticated-orcid":true,"given":"Pamela","family":"Leece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-7586","authenticated-orcid":true,"given":"Charlotte","family":"Munro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes","family":"Besharh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-1965","authenticated-orcid":true,"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"pmed.1004748.ref001","author":"National Institute on Drug Abuse"},{"key":"pmed.1004748.ref002","volume-title":"Opioid- and stimulant-related harms in Canada","author":"Federal, Provincial, and Territorial Special Advisory Committee on the Epidemic of Opioid Overdoses","year":"2024"},{"key":"pmed.1004748.ref003","volume-title":"Patterns of medication and healthcare use among people who died of an opioid-related toxicity during the COVID-19 pandemic in Ontario","author":"T Gomes","year":"2022"},{"key":"pmed.1004748.ref004","doi-asserted-by":"crossref","first-page":"104392","DOI":"10.1016\/j.drugpo.2024.104392","article-title":"Trends in opioid toxicities among people with and without opioid use disorder and the impact of the COVID-19 pandemic in Ontario, Canada: a population-based analysis","volume":"127","author":"S Ledlie","year":"2024","journal-title":"Int J Drug Policy"},{"key":"pmed.1004748.ref005","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study","volume":"368","author":"LA Pearce","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"pmed.1004748.ref006","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis","volume":"78","author":"Jr Santo T","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"pmed.1004748.ref007","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"L Sordo","year":"2017","journal-title":"BMJ"},{"issue":"9","key":"pmed.1004748.ref008","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/add.14991","article-title":"Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services","volume":"115","author":"N Krawczyk","year":"2020","journal-title":"Addiction"},{"issue":"8","key":"pmed.1004748.ref009","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.27290","article-title":"Initiation and dose of methadone monotherapy vs combination therapy, 2015 to 2023","volume":"8","author":"R Garg","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"21","key":"pmed.1004748.ref010","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder","volume":"332","author":"B Nosyk","year":"2024","journal-title":"JAMA"},{"issue":"7","key":"pmed.1004748.ref011","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/add.15862","article-title":"Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study","volume":"117","author":"T Gomes","year":"2022","journal-title":"Addiction"},{"issue":"7","key":"pmed.1004748.ref012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18389","article-title":"Duration of methadone and buprenorphine-naloxone treatment","volume":"8","author":"RA Kleinman","year":"2025","journal-title":"JAMA Netw Open"},{"key":"pmed.1004748.ref013","author":"LKM Bromley","year":"2021"},{"issue":"38","key":"pmed.1004748.ref014","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.241173","article-title":"Management of opioid use disorder: 2024 update to the national clinical practice guideline","volume":"196","author":"I Yakovenko","year":"2024","journal-title":"CMAJ"},{"key":"pmed.1004748.ref015","volume-title":"Federal guidelines for opioid treatment programs. PEP24-02\u2013011","author":"Substance Abuse and Mental Health Services Administration","year":"2024"},{"key":"pmed.1004748.ref016","unstructured":"British Columbia Centre on Substance Use, BC Ministry of Health, and BC Ministry of Mental Health and Addictions. A guideline for the clinical management of opioid use disorder. Published November 2023. Available from: https:\/\/www.bccsu.ca\/opioid-use-disorder\/"},{"issue":"5","key":"pmed.1004748.ref017","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/ADM.0000000000001362","article-title":"Induction to methadone 80\u2009mg in the first week of treatment of patients who use fentanyl: a case series from an outpatient opioid treatment program","volume":"18","author":"S Steiger","year":"2024","journal-title":"J Addict Med"},{"issue":"4","key":"pmed.1004748.ref018","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/ADM.0000000000001473","article-title":"Relationship between methadone induction dosing and retention in treatment in opioid treatment programs","volume":"19","author":"RC Sherrick","year":"2025","journal-title":"J Addict Med"},{"key":"pmed.1004748.ref019","doi-asserted-by":"crossref","first-page":"108832","DOI":"10.1016\/j.jsat.2022.108832","article-title":"Adapting methadone inductions to the fentanyl era","volume":"141","author":"M Buresh","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"pmed.1004748.ref020","unstructured":"College of Physcians and Surgeons of Ontario. Methadone maintenance treatment policy rescinded: CPSO - Dialogue. March 2021. [cited 6 Oct 2024]. Available from: https:\/\/dialogue.cpso.on.ca\/articles\/methadone-maintenance-treatment-policy-rescinded"},{"key":"pmed.1004748.ref021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","article-title":"Comparing Canadian and United States opioid agonist therapy policies","volume":"74","author":"KC Priest","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"14","key":"pmed.1004748.ref022","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"CB Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"pmed.1004748.ref023","doi-asserted-by":"crossref","first-page":"209004","DOI":"10.1016\/j.josat.2023.209004","article-title":"Safety of rapid inpatient methadone initiation protocol: a retrospective cohort study","volume":"148","author":"S Racha","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"1","key":"pmed.1004748.ref024","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s40001-023-01538-0","article-title":"Initiation and rapid titration of methadone and slow-release oral morphine (SROM) in an acute care, inpatient setting: a case series","volume":"28","author":"L Rodger","year":"2023","journal-title":"Eur J Med Res"},{"issue":"5","key":"pmed.1004748.ref025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/ADM.0000000000000507","article-title":"Initiation and rapid titration of methadone in an acute care setting for the treatment of opioid use disorder: a case report","volume":"13","author":"P Hemmons","year":"2019","journal-title":"J Addict Med"},{"issue":"4","key":"pmed.1004748.ref026","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"E von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"pmed.1004748.ref027","doi-asserted-by":"crossref","first-page":"103601","DOI":"10.1016\/j.drugpo.2022.103601","article-title":"Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada","volume":"102","author":"S Young","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"8","key":"pmed.1004748.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201120","article-title":"Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: a validation study","volume":"13","author":"L Lapointe-Shaw","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"pmed.1004748.ref029","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.11398","article-title":"Short-acting, full agonist opioids during initiation of opioid agonist treatment in the fentanyl era","volume":"7","author":"AJ Saxon","year":"2024","journal-title":"JAMA Netw Open"},{"key":"pmed.1004748.ref030","unstructured":"Substance Abuse and Mental Health Services Administration. Methadone treatment for opioid use disorder: treatment guidance. Updated December 13, 2023. [cited 16 Mar 2025]. https:\/\/www.samhsa.gov\/substance-use\/treatment\/opioid-treatment-program\/methadone-guidance"},{"key":"pmed.1004748.ref031","doi-asserted-by":"crossref","first-page":"209616","DOI":"10.1016\/j.josat.2024.209616","article-title":"\u201cI still can feel the sickness\u201d: withdrawal experiences of people on methadone maintenance treatment","volume":"170","author":"D Frank","year":"2025","journal-title":"J Subst Use Addict Treat"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:22:45Z","timestamp":1775755365000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004748"}},"subtitle":[],"editor":[{"given":"Louisa","family":"Degenhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004748","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}